Nature’s Innovation, Inc.
FDA issued a warning letter to Nature’s Innovation, Inc. (Buford, GA, United States) on Aug 18, 2023, citing 21 CFR 201.66. Subject: Unapproved New Drugs, Misbranded.
From the letter: “Your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention…”
At a glance
What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.
- Violations
- 4 findings · 1 issue type
- Cited
- 21 CFR 201.66
- Response due
- 15 working days after receipt of this letter
- FDA asks for
- 5 actions
- Named as possible actions
- Seizure, injunction
- Issued by
- Center for Drug Evaluation and Research
- Published status
- No close-out recorded
AI assisted findings
Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.
01Labeling, claims & marketingProducts are unapproved new drugs marketed with disease treatment claims.
Your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body.
02Labeling, claims & marketingProducts lack GRASE status and are new drugs without approved applications.
Your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p).
03Labeling, claims & marketingNo FDA-approved application is in effect for the products.
No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these products.
04Labeling, claims & marketingInactive ingredients are actually active due to promotional claims.
Your above-mentioned drugs include non-homeopathic ingredients that, although listed as “inactive ingredients,” are considered active ingredients under 21 C.F.R. 201.66(b)(2) because they are promoted on your website in various places with claims to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or any function of the body.
What FDA requested
- Provide specific steps taken to correct the violations
- Provide explanation of each step being taken to prevent recurrence of violations
- Provide copies of related documentation
- If products are believed not in violation, provide reasoning and supporting information
- If corrective action cannot be completed within 15 working days, state reason for delay and time for completion
FDA Warning Letter
30 paragraphs · 5 sectionsText as published on FDA.gov, retrieved Sep 8, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)
1Introduction
3 paragraphs
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.naturasil.com in July 2023. We also reviewed your social media websites at www.instagram.com/naturasil/ and www.facebook.com/Naturasil/, where you direct consumers to your website, www.naturasil.com, to purchase your products. The FDA has observed that your website offers your “Naturasil Molluscum Treatment Kit”1 and “Naturasil Shingles” products for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act.
Molluscum contagiosum is not a condition amenable to self-diagnosis and treatment, and there are no legally marketed over-the-counter (OTC) drug products to treat this condition. Molluscum contagiosum is a viral skin infection characterized by small, raised lesions on the skin that are known as Mollusca. Molluscum affects both children and adults; however, it is more common in children. In healthy individuals, the lesions usually disappear spontaneously within 6 to 12 months, although in some cases, it could take years to resolve. In sexually active individuals, the lesions found in the genital region are considered a sexually transmitted disease/infection (STD/STI). In addition, patients with new or existing skin lesions should seek out a healthcare professional to be evaluated. A healthcare professional is needed to rule out the possibility of a more serious condition, such as, skin cancer, fungal infection, and for the genitalia, anogenital warts. Your “Naturasil Molluscum Treatment Kit” is especially concerning from a public health perspective because it is marketed for use in children. In addition, FDA is concerned that people are forgoing or delaying proper diagnosis and treatment of a potentially serious, undiagnosed health condition by purchasing and using an unapproved drug product claiming to treat molluscum contagiosum.
Your “Naturasil Shingles” product is concerning for various reasons. Shingles is a serious condition that is not amenable to either diagnosis or treatment by a lay person, and there are no legally marketed OTC drug products to treat this condition. Treatment of shingles requires antiviral therapy, and early treatment is key to promote healing of the rash and reduce the severity and duration of pain. A person with shingles can potentially spread the varicella-zoster virus to others. Furthermore, FDA is concerned that people who use an unapproved drug product claiming to treat shingles are putting themselves at risk for developing serious complications, e.g., postherpetic neuralgia (long-term nerve pain), herpes zoster ophthalmicus (which can lead to vision loss), and skin infections.
2Unapproved New Drugs
2 paragraphs
Based on a review of your websites, your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body.
Examples of claims from your websites that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:
3Naturasil Molluscum Treatment Kit
5 paragraphs
On the product webpage for “Naturasil Molluscum Treatment Kit,” https://www.naturasil.com/pages/molluscum-contagiosum-treatment-kit?_pos=12&_sid=acf8ae577&_ss=r: • “NATURASIL FOR MOLLUSCUM IS THE NUMBER 1 All Natural, No Acids, Pain-Free Remedy for Children and Adults, Made in the USA. Parent Approved!” • “Naturasil for Molluscum Treatment Kit . . . Get rid of Molluscum at home with this PAIN-FREE BREAKTHROUGH 100% Natural Molluscum Contagiosum Treatment. CHILD-SAFE (2 years old & above) Causes Molluscum to dry up and flake away painlessly over time.” • “Effectively & gently clears Molluscum bumps Relieves itching & discomfort” • “Naturasil for Molluscum Treatment Kit for Children and Adults… Best for treating Genitals and other sensitive areas and children or adults with large or severe Molluscum outbreaks.”
From a September 6, 2022 blog post entitled, “MOLLUSCUM CONTAGIOSUM | SIGNS AND SYMPTOMS OF AN INFECTION,” https://www.naturasil.com/blogs/naturasil-blogs/molluscum-contagiosum-signs-symptoms?_pos=8&_sid=c37dd889d&_ss=r: • “Regardless, effective natural remedies, such as the Naturasil Molluscum Contagiosum Treatments are designed to penetrate viral cells to quicken your recovery time.”
From a June 10, 2022 blog post entitled, “Natural Treatment Options for Molluscum Contagiosum,” https://www.naturasil.com/blogs/naturasil-blogs/natural-treatment-options-for-molluscum-contagiosum?_pos=7&_sid=c37dd889d&_ss=r: • “Naturasil's Molluscum Contagiosum Treatment was constructed with the most potent ingredients throughout the herbal industry. Each compound injects a vast array of nutrients capable of hindering the health and development of the molluscum virus.” • “Naturasil for Molluscum is a completely natural treatment solution that eradicates this awful condition often found in children quickly and safely without the use of harsh chemicals.”
On your Facebook social media page https://www.facebook.com/Naturasil/: • March 15, 2023 post: “Most Trusted Molluscum Brand Effectively & #gently #clears #Molluscum #bumps #Relieves #itching & #discomfort” • October 8, 2022 post – Your post includes some of the following hashtags: “#molluscumcontagiosum,” “#kidsafe,” “#natural,” “#remedy,” “#treatment” with an image of your “Naturasil Molluscum Treatment Kit” product and text that reads “I wish I could share before and after photos, his molluscum is almost gone with a few more treatments it will be . . . My 3 year [old] has had it for 1.5 years and nothing worked. Thank you soo [sic] much Naturasil.”
On your Instagram social media page https://www.instagram.com/naturasil/?hl=en: • August 4, 2022 post – Your post includes an image of your “Naturasil Molluscum Treatment Kit” product and text that reads “It works! We’ve been using the product for a few weeks and I can definitely see an improvement in my daughter’s sports. Some are shrinking and others are drying up. We have had the best results when applying it 4-5 times a day. It requires patience, but is the only thing I’ve seen that works!”
4Naturasil Shingles
2 paragraphs
On the product webpage for “Naturasil Shingles,” https://www.naturasil.com/pages/shingles-15ml: • “Naturasil for Shingles assists the body in reducing and eliminating shingles outbreaks naturally and effectively, without the harmful side effects found in many shingles treatment drugs, through a topical application that is absorbed into the skin at the site of the outbreak.” • “The active components of our shingles treatments are high levels of neral, geraniol, alpha-terpinenes, and linalool. All anti-viral and anti-inflammatory compounds are found in Melissa Officinalis, melaleuca alternifolia, agathophyllum aromatica, and other critical anti-viral plant extracts. These compounds have anti-viral properties and effectively combat the herpes zoster virus that causes shingles.” • “END THE SHINGLE NIGHTMARE NOW. Get the all-natural, #1 REMEDY, complete package for treating YOUR Shingles.”
Your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these products.2 Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
5Conclusion
3 paragraphs
This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.
This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.
Citations and trends
Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.
Regulations
Issue types
Record details
- Issuing center
- Center for Drug Evaluation and Research
- Issuing office
- Center for Drug Evaluation and Research
- Location
- Buford, GA, United States
- Letter posted date
- Aug 22, 2023
- Letter issue date
- Aug 18, 2023
- Addressed to
- CEO
- Inspection dates
- Not recorded
- Response window
- 15 working days after receipt of this letter
Read the source clause
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations.
- Record length
- 1,788 words · 1 recorded redactions
- Published status
- No published close-out
- Original letter
- View on FDA.gov (opens in a new tab)
- Dataset last checked
- Nov 11, 2026 · How this is built
A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.